Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, ...
Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...
The next-generation weight loss drug that’s ‘as effective as Mounjaro – WITHOUT Ozempic side effect’
A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...
India Today on MSN
Novo Nordisk partners with Emcure to expand Wegovy's reach in India
Wegovy, which uses semaglutide to aid weight loss, was introduced in India in June 2024, two months after Mounjaro's debut.
Under the agreement, the Danish drugmaker will sell Poviztra 2.4 milligram (mg) semaglutide injection in India as a separate ...
The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...
Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...
Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...
Poviztra (semaglutide injection 2.4 mg) is the second brand of Wegovy, Novo Nordisk’s blockbuster obesity medication, which ...
Emcure tie-up to sell WeGovy in India under a new brand name comes two weeks Cipla signed a similar deal with Eli Lilly for Mounjaro.| Business News ...
Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd are preparing to enter the fast-growing market for Semaglutide — a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results